Loading page
Loading page
Loading substance route
Methcathinone is considered highly psychologically addictive with abuse potential similar to amphetamines. Extreme compulsive redosing is commonly reported, partly because initial effects may seem subtle, leading users to take additional doses. Animal studies have demonstrated pronounced drug-seeking behavior and craving.
Physical dependence can develop with prolonged or high-dosage use, producing methamphetamine-like withdrawal symptoms. Discontinuation after chronic use is associated with depression, anxiety, anhedonia, and cognitive fatigue, though psychological withdrawal symptoms appear more prominent than classical physical dependence.
Methcathinone places considerable strain on the cardiovascular system, causing hypertension and tachycardia during use; risk of stroke or heart attack is elevated, particularly at high doses or with repeated administration.
Illicitly manufactured methcathinone synthesized using potassium permanganate oxidation may contain manganese contamination, causing neurotoxicity with Parkinson-like symptoms (manganism); this risk is specific to contaminated batches rather than the pure compound.
Severe dehydration is reported more frequently with methcathinone than with other stimulants, creating risk of rhabdomyolysis which can be life-threatening if untreated; adequate hydration during use is essential to protect kidney function.
Insufflation is corrosive to the nasal mucosa in a manner similar to methamphetamine, causing long-lasting nosebleeds with repeated intranasal use.
Chronic high-dose use may result in acute mental confusion ranging from mild paranoia to psychosis. These symptoms typically disappear quickly if use is stopped. Paranoia is also listed among acute cognitive effects at higher doses.
Methcathinone was first synthesized in the United States in 1928. The compound was subsequently patented by the pharmaceutical company Parke-Davis in 1957. During the 1930s and 1940s, the Soviet Union employed the substance therapeutically as an antidepressant, where it was known as ephedrone…
UN Convention on Psychotropic Substances 1971 (Schedule I)
Classified as a Schedule 9 prohibited substance under the Poisons Standard. Schedule 9 substances are considered to have no therapeutic use and high potential for abuse, making possession, production, and distribution illegal without specific authorization.
12 sources cited